ERBB2 and triple-negative breast carcinoma: The cohort was heterogeneous regarding hormone receptors and human epidermal growth factor receptor 2 (HER2) status: Fifty patients had hormone receptor‐positive and HER2‐negative breast cancer (83.3%), nine had HER2‐positive breast cancer (15.7%), and one patient had triple negative breast cancer (2%).